cilia and flagella associated protein 410Genealiases: C21orf2 · LRRC76 · RDMS · SMDAX · YF5/A2
Q-omics provides the consensus-scored CFAP410 profile across patient tissues and cancer cell-line models. CFAP410 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, CFAP410 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, CFAP410 RNA expression shows 17,102 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight PAAD, KICH, and TGCT as cancer lineages where CFAP410 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CFAP410 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CFAP410 survival associations across molecular data types. CFAP410 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (5) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CFAP410 RNA expression–survival associations across cancer types. High CFAP410 expression shows unfavorable associations in COAD and CESC, but favorable associations in PAAD, HNSC, KIRP and DLBC. The PAAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for CFAP410 RNA expression.
This table summarizes CFAP410 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in KICH for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CFAP410. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CFAP410 shows lower tumor expression in KICH, THCA, LUAD, KIRP and UCEC and higher tumor expression in CHOL. The KICH box plot shows higher CFAP410 RNA expression in normal versus tumor tissue (log2 FC = −1.042, t-test p < 0.001).
This table shows molecular features associated with CFAP410 in patient tissues and cancer cell lines. In patient samples, CFAP410 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, CFAP410 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and SKIN.
